Introduction
Continuous glucose monitoring (CGM) has proven to be beneficial for diabetes patients, especially children with type 1 diabetes and adult type 1 patients with nocturnal hypoglycemic events. State-of-the-art continuous glucose monitoring systems are based on electrochemical sensors which measure glucose in the subcutaneous adipose tissue. In order to create a closed loop system or an artificial pancreas a European research consortium combines these sensors with recently developed algorithms and insulin pumps to infuse the calculated insulin doses. Diabetes patients will benefit from such systems because they can provide better glycemic control and reduce hyper-and hypoglycemic episodes. But the use of such a closed loop system requires two body interfaces: patients have to insert the glucose sensor at one site of the abdomen and the insulin infusion catheter at a second site. Furthermore, it is necessary to wear two devices, the glucose sensor and the insulin pump. In order to overcome the drawbacks of current glucose monitoring and insulin infusion methods, we aimed to develop an integrated catheter for simultaneous glucose measurement and insulin delivery.
Methods
A single-port body interface integrates the glucose sensor into the insulin infusion catheter which allows using a single body interface for both functions of an AP system: glucose measurement and insulin infusion. Furthermore, a single-port system solves two fundamental technical problems in continuous glucose monitoring. First, insertion and removal of the sensor imposes no additional burden on the patient because the sensor is automatically exchanged with the insulin infusion set. Second, the sensor is located in the body for 3 days maximum, minimizing biocompatibility issues and long term drift. The glucose sensor comprises a glucose oxidase layer which is covered by a layer of a luminescent dye. The luminescence of the dye is quenched by oxygen. As the enzyme reaction consumes oxygen for glucose oxidation the sensor signal corresponds to glucose concentrations in the tissue. A reference oxygen sensor is used to compensate for fluctuations in tissue oxygen levels. Both sensors are applied as rings on the outer surface of the catheter. The contactless signal read-out is performed by an optical module attached to the skin directly above the catheter via transcutaneous NIR-radiation. 
Results
In proof-of-principle studies we showed that frequencydomain measurements in the near infrared region (NIR) are feasible in skin and subcutaneous tissue. In-vitro characterization was performed with phosphate buffered saline solutions containing 0, 45, 90, 180 and 360 mg/dl glucose. The glucose sensor showed a good linearity of the measured phase shift in the tested concentration range with a sensor slope of 0.032°/mg/dl. The sensor drift was evaluated in a 50 h experiment at a low glucose concentration of 45 mg/dl and a high glucose concentration of 360 mg/dl. The maximum sensor drift of 0.38%/h indicates that the sensor can be recalibrated in a 12 h interval and the error deriving from the sensor drift will be smaller than 5%. Furthermore, in-vivo experiments in pigs demonstrated that glucose concentrations measured subcutaneously followed the glucose profile in blood and that simultaneous insulin delivery at the site of measurement did not affect the measured glucose concentration. Adjusted glucose profiles were maintained per intravenous glucose infusion and subcutaneous insulin infusion using our new integrated glucose sensitive catheters and included hypo-and hyperglycemic episodes (40 -250 mg/dl). The insulin infusion rate was adapted to common insulin infusion regimes with a basal rate of 1.2 U/h. Glucose sensor values were recorded in 5 min intervals and reference blood glucose values were also taken every 5 min and were analyzed with a Super GL glucose analyzer. The glucose sensors were tested in three groups with 6 sensors each using different infusion regimes. One sensor group was tested with an insulin infusion rate of 1.2 U/h, a second sensor group was tested with an infusion of 0.9% NaCl solution (infusion rate: 12 µl/h) and a third group was tested with no infusion. The average median absolute relative error (MARE) was 21.6 ± 5.7% for the insulin infusion group, 18.1 ± 5.8% for the NaCl infusion group and 19.2 ± 7.9% for the group with no infusion. There was no significant difference between the 3 infusion groups. 
Discussion
These results demonstrate a good proof of concept for our novel single-port system, which combines continuous glucose monitoring with insulin infusion in one device. The sensor-derived glucose profiles correlated well with the reference blood-glucose values, independent of the infusion type via the sensing catheter. After further miniaturization and biocompatibility improvement the system will be evaluated in a clinical setting.
